Lineage Cell Therapeutics Inc (LCTX)

[bobby2loaves]

While BTX will indeed only retain 3mm shares or so of AGE after the spinoff, there were some interesting twists mentioned in the details of the AgeX / Juvenescence deal that may give them a little more exposure to AGE shares in 2019:

(1) Biotime can elect to take the 2nd half of the deal as stock in the Juvenescence IPO

(2) Biotime would get awarded shares of the Juvenescence IPO at 7.2mm shares x whatever the share price of AgeX was at the time of the Juvenescence IPO.

So, Biotime is not only retaining 3mm shares or so of AgeX post-spinoff, but also able to re-claim some exposure to those 7.2mm shares, depending of how large a holding AgeX is in Juvenescence's portfolio at the time of the IPO. It probably ultimately only essentially exposes BTX to another couple million shares if they exercise the option, but a cool alternative to the cash + 7% interest if you ask me, especially if the AGE share price performs well in the interim.